[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-hepatitis-d-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-hepatitis-d-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,68,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100651656","phase-2-a-study-to-assess-the-safety-pharmacokinetics-and-efficacy-of-abi-6250-in-participants-with-chronic-hepatitis-d-virus-infection-100651656",false,"NCT07762027","A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection","A Phase 2, Multicenter, Open Label, Parallel-Group Study of the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection","Inclusion Criteria:\n\n* Participant has a body mass index ≥18.0 and \\\u003C35.0 kg\u002Fm2 at Screening\n* Other than HBV and HDV infection, the participant is in good health (as determined by the Investigator) based on medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory results.\n* Participant agrees to comply with protocol-specified contraception requirements.\n\nExclusion Criteria:\n\n* Participant has a current coinfection with acute hepatitis A virus (HAV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).\n* Participant has a history of any significant food or drug-related allergic reactions such as anaphylaxis, Stevens-Johnson syndrome, or urticaria.\n* Participant has been treated for HDV infection in the past 6 months prior to Day 1.\n* Participant took part in another clinical trial of a drug or device (other than for HDV infection) whereby the last study drug\u002Fdevice administration is within 30 days or 5 half-lives, whichever is longer, prior to Day 1.","ALL","18 Years","70 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is designed to assess safety, pharmacokinetics, and efficacy ABI-6250 in participants with Chronic Hepatitis D Virus Infection.",[27],"Chronic Hepatitis D Infection","NOT_YET_RECRUITING","2026-08-07",{"date":31,"type":32},"2026-08-13","ACTUAL",{"date":34,"type":21},"2026-10",{"date":36,"type":21},"2028-09",{"name":38,"class":39},"Assembly Biosciences","INDUSTRY",22,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100608388","phase-3-a-trial-evaluating-brelovitug-bjt-778-vs-bulevirtide-for-the-treatment-of-chronic-hepatitis-delta-infection-azure-2-100608388","NCT07200908","A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)","A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)","Key Inclusion Criteria:\n\n1. Willing and able to provide written informed consent\n2. Chronic HDV infection\n3. HDV RNA \\>500 IU\u002FmL at Screening\n4. ALT \\>ULN at Screening\n5. Willing to take or already taking HBV neucleos(t)ide therapy.\n\nKey Exclusion Criteria:\n\n1. Pregnant or nursing females\n2. Unwilling to comply with contraception requirements during the study\n3. Difficulty with blood collection and\u002For poor venous access for the purposes of phlebotomy\n4. Clinical hepatic decompensation (i.e., ascites, encephalopathy variceal hemorrhage).\n5. Solid organ or bone marrow transplantation\n6. Presence of other liver disease(s) (non-HBV\u002FHDV), such as nonalcoholic steatohepatitis (NASH), alcohol associated hepatitis, cholestatic liver disease, hepatocellular carcinoma.\n\nNote - Other protocol-defined Inclusion\u002FExclusion criteria apply.","99 Years",{"count":50,"type":21},172,[52],"PHASE3","This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD). The main goal of this study is to test the effectiveness of brelovitug compared to bulevirtide as a long-term treatment in patients with chronic HDV infection.",[27],[56],"Hepatitis Delta virus, HDV, Hepatitis D infection; Hepatitis D virus","RECRUITING","2026-06-11",{"date":60,"type":32},"2026-06-15",{"date":62,"type":32},"2025-08-27",{"date":64,"type":21},"2029-09-30",{"name":66,"class":39},"Mirum Pharmaceuticals, Inc.",48,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":18,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100631351","phase-3-a-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-libevitug-in-participants-with-chronic-hdv-infection-d-clear-study-100631351","NCT07499544","A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)","A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Assess Efficacy and Safety of Libevitug Injection in Participants With Chronic Hepatitis Delta Virus Infection (D-clear Study)","Inclusion Criteria:\n\n* Willing to sign written informed consent;\n* Chronic HDV history with at least 6 months;\n* HDV RNA ≥500 IU\u002FmL at screening;\n* ALT \\>1ULN and \\\u003C10×ULN;\n* Able to communicate well and comply with protocol.\n\nExclusion Criteria:\n\n* Concomitant decompensated cirrhosis;\n* Previous or current HCC or suspicion for HCC;\n* Participants with history of alcoholic liver disease, nonalcoholic steatohepatitis or other clinically significant chronic liver diseases not caused by HDV\u002FHBV;\n* Participants with active hepatitis C infection, or HIV infection;\n* Alcohol abuse or drug addiction within 1 year;\n* Participants have participated in other clinical trial within 1 month;\n* Pregnant, lactating women.","12 Years",{"count":77,"type":21},160,[52],"This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.",[27],[82,83],"Hepatitis Delta Virus (HDV)","Viral hepatitis","2026-06-08",{"date":86,"type":32},"2026-06-10",{"date":88,"type":32},"2026-04-22",{"date":90,"type":21},"2030-01-29",{"name":92,"class":39},"Huahui Health",1,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":105,"studyType":106,"phases":4,"briefSummary":107,"conditions":108,"keywords":113,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":126},"100535188","find-hdv-and-determine-its-status-in-turkey-100535188","NCT06248580","Find HDV and Determine Its Status in Turkey","Find HDV and Determine Its Status in Turkey \"SITU(HD)VATION\"","SITUHDVATION","Inclusion Criteria:\n\n* Adults (Age≥18)\n* Being HBsAg positive for at least six months\n* Being a citizen of the Republic of Türkiye\n\nExclusion Criteria:\n\n* There are no exclusion criteria in this study.",true,{"count":104,"type":21},20000,"13 Months","OBSERVATIONAL","The aim of these study to determine the prevalence of hepatitis Delta virus (HDV) infections and the prognosis of HDV patients in Turkey's southeast. The investigators intend to arrange training sessions for 250 family physicians in Diyarbakir, Batman, Mardin, and Sanliurfa in order to determine those goals. The investigators will talk about diagnosing hepatitis B virus (HBV), HDV, hepatitis C virus (HCV), and Human Immunodeficiency virus (HIV) infections during these events. To ensure that patients with simultaneous HDV infection are evaluated for HIV\u002FHCV and to detect liver fibrosis with a non-invasive method.",[27,109,110,111,112],"Fibrosis, Liver","Hepatocellular Carcinoma","Cirrhosis, Liver","Transmission Vertical",[114,110,115],"Chronic hepatitis D","Liver Cirrhosis","2024-08-08",{"date":118,"type":32},"2024-08-12",{"date":120,"type":32},"2024-03-11",{"date":122,"type":21},"2025-03-01",{"name":124,"class":125},"Yaşar Bayındır, MD","OTHER",2]